February 10, 2012 at 09:00 AM EST
A Forward Look, The Year Ahead - Featured Research on AMAG Pharmaceuticals, Inc. and Akorn, Inc.

HONG KONG -- (Marketwire) -- 02/10/12 -- Today, www.BollingerReport.com introduced featured coverage of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Akorn, Inc. (NASDAQ: AKRX). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=AMAG&sm2=AKRX.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Bollinger Report screened and selected AMAG Pharmaceuticals, Inc. for its current position within the healthcare industry. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. A copy of this report featuring AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) is available at: www.BollingerReport.com/index.php?sm1=AMAG.

Bollinger Report is featuring Akorn, Inc. for its changing role within the healthcare industry. Akorn, Inc. manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, the Company has marketed and distributed vaccines purchased from outside sources. The Company operates in three segments: ophthalmic; hospital drugs and injectables, and contract services. To download researches and analysis on Akorn, Inc. (NASDAQ: AKRX) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=AKRX.

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact:

Martin Schwartz
Email Contact
www.BollingerReport.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here